<p>加利福尼亚州红木城 --（商业资讯）--Adicet Bio, Inc.（纳斯达克代码：ACET）是一家临床阶段的生物技术公司，专注于发现和开发用于自身免疫疾病和癌症的异体伽马δ T 细胞疗法，今天宣布其董事会决定实施 Adicet 普通股的 1 比 16 反向股票拆分，面值为每股 0.0001 美元。</p>
<p>董事会批准的反向股票拆分比例在 2025 年 12 月 19 日举行的 Adicet 2025 年特别股东大会上由公司股东授权的反向股票拆分比例的先前披露范围内。反向股票拆分将于 2025 年 12 月 30 日东部时间凌晨 12:01 生效，Adicet 的普通股将于 2025 年 12 月 30 日开盘时在纳斯达克资本市场以拆分调整后的基础开始交易。反向股票拆分生效时，Adicet 的普通股将被分配 CUSIP 号码 007002207。</p>
<p>当反向股票拆分生效时，Adicet 已发行的每十六（16）股普通股将合并为一股已发行的普通股，面值不变。这将使已发行的普通股数量从大约 1.533 亿股减少到大约 960 万股。反向股票拆分不会影响 Adicet 授权的普通股的绝对数量，仍将保持在 3 亿股，但 Adicet 未来可发行的普通股总数将增加。</p>
<p>还将对 Adicet 的股权激励计划下授予和可发行的普通股数量进行比例调整，以及 Adicet 的未到期股票期权和其他股权证券的行使价格和可发行股份数量。所有未到期的预先融资认股权证也将根据其条款进行调整，这将导致对可通过行使这些认股权证发行的股份数量和这些认股权证的行使价格进行比例调整。</p>
<p>在反向股票拆分中不会发行任何零碎股份。原本有权获得零碎股份的股东将自动有权获得现金以代替这些零碎股份。</p>
<p>以账面形式持有股份或通过银行、经纪人或其他代理人持有股份的股东无需采取任何行动，反向股票拆分的结果将在 2025 年 12 月 30 日或之后反映在他们的账户中。这些受益持有人可以联系他们的银行、经纪人或代理人以获取更多信息。</p>
<p>反向股票拆分旨在使 Adicet 重新符合纳斯达克资本市场持续上市的最低出价要求。</p>
<p><strong>关于 Adicet Bio, Inc.</strong></p>
<p>Adicet Bio, Inc.是一家临床阶段的生物技术公司，专注于发现和开发用于自身免疫疾病和癌症的异体伽马δ T 细胞疗法。Adicet 正在推进一系列 “现成” 的伽马δ T 细胞，这些细胞经过嵌合抗原受体（CARs）工程改造，以促进患者的持久活性。有关更多信息，请访问我们的网站 https://www.adicetbio.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 Adicet 根据 1995 年《私人证券诉讼改革法》所定义的 “前瞻性声明”，涉及 Adicet 的业务和运营。词语 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将” 和类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。这些前瞻性声明包括但不限于关于反向股票拆分的时间和完成情况、反向股票拆分的预期效果以及 Adicet 普通股在拆分调整后基础上的交易情况，以及反向股票拆分对 Adicet 重新符合纳斯达克上市标准的能力的影响。</p>
<p>本新闻稿中的任何前瞻性声明均基于管理层对未来事件的当前预期和信念，并受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些前瞻性声明中所列或暗示的结果存在重大和不利的差异，包括但不限于全球经济状况和公共卫生紧急情况对 Adicet 业务和财务结果的影响，包括对我们临床前和临床研究、业务运营、员工招聘和留任以及筹集额外资本能力的干扰；Adicet 执行其战略的能力，包括在预期时间内获得必要的监管批准（如果有的话）；临床前或临床研究的积极结果（包括中期结果）不一定能预测未来或正在进行的研究的结果；临床研究可能未能证明 Adicet 产品候选者的安全性和有效性，这将阻止、延迟或限制监管批准和商业化的范围；美国食品和药物管理局及其他外国监管机构的监管批准过程漫长、耗时且本质上不可预测；以及 Adicet 满足生产和产品发布预期的能力。有关这些及其他风险和不确定性的讨论，以及可能导致 Adicet 实际结果与前瞻性声明中所包含的结果不同的其他重要因素，请参见 Adicet 最近的 10-K 表格年度报告、10-Q 表格季度报告及其后续向美国证券交易委员会（SEC）提交的文件中标题为 “风险因素” 的部分，以及 Adicet 在 SEC 的其他文件中对潜在风险、不确定性和其他重要因素的讨论。本新闻稿中的所有信息均截至发布之日，Adicet 不承担更新该信息的义务，除非法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjY2NjE3OTNyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjY2NjE3OTNyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251226661793/en/</p>
<p><strong>Adicet Bio, Inc.</strong></p>
<p><strong>投资者和媒体联系人</strong></p>
<p>Anne Bowdidge</p>
<p>abowdidge@adicetbio.com</p>
<p><strong>Penelope Belnap</strong></p>
<p><strong>Precision AQ</strong></p>
<p>212-362-1200</p>
<p>Penelope.belnap@precisionaq.com</p>
<p>来源：Adicet Bio, Inc.</p>

ACET

<p>Adicet Bio, Inc. 宣布将于 2025 年 12 月 30 日实施 1 股换 16 股的反向股票拆分。此举旨在重新符合纳斯达克的最低报价要求。反向拆分将使流通股从约 1.533 亿股减少至 960 万股，而不会影响总授权股份。股权激励计划和股票期权将进行相应的调整。不会发行零碎股份；将提供现金作为替代。调整后的交易将在生效日期当天在纳斯达克开始</p>

<p>REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0001 per share.</p>
<div class="lb-trans"><p>加利福尼亚州红木城 --（商业资讯）--Adicet Bio, Inc.（纳斯达克代码：ACET）是一家临床阶段的生物技术公司，专注于发现和开发用于自身免疫疾病和癌症的异体伽马δ T 细胞疗法，今天宣布其董事会决定实施 Adicet 普通股的 1 比 16 反向股票拆分，面值为每股 0.0001 美元。</p>
</div><p>The reverse stock split ratio approved by the board of directors is within the previously disclosed range of ratios for a reverse stock split authorized by the stockholders of the company at the 2025 Special Meeting of Stockholders of Adicet held on December 19, 2025. The reverse stock split will take effect at 12:01 a.m. Eastern Time on December 30, 2025, and Adicet’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on December 30, 2025. The CUSIP number of 007002207 will be assigned to Adicet’s common stock when the reverse stock split becomes effective.</p>
<div class="lb-trans"><p>董事会批准的反向股票拆分比例在 2025 年 12 月 19 日举行的 Adicet 2025 年特别股东大会上由公司股东授权的反向股票拆分比例的先前披露范围内。反向股票拆分将于 2025 年 12 月 30 日东部时间凌晨 12:01 生效，Adicet 的普通股将于 2025 年 12 月 30 日开盘时在纳斯达克资本市场以拆分调整后的基础开始交易。反向股票拆分生效时，Adicet 的普通股将被分配 CUSIP 号码 007002207。</p>
</div><p>When the reverse stock split becomes effective, every sixteen (16) of Adicet’s issued shares of common stock will be combined into one issued share of common stock, without any change to the par value per share. This will reduce the number of outstanding shares of common stock from approximately 153.3 million shares to approximately 9.6 million shares. The reverse stock split will not affect the absolute number of Adicet’s authorized shares of common stock, which will remain at 300,000,000, but the total number of shares of Adicet’s common stock available for future issuance will increase.</p>
<div class="lb-trans"><p>当反向股票拆分生效时，Adicet 已发行的每十六（16）股普通股将合并为一股已发行的普通股，面值不变。这将使已发行的普通股数量从大约 1.533 亿股减少到大约 960 万股。反向股票拆分不会影响 Adicet 授权的普通股的绝对数量，仍将保持在 3 亿股，但 Adicet 未来可发行的普通股总数将增加。</p>
</div><p>Proportional adjustments will also be made to the number of shares of common stock awarded and available for issuance under Adicet’s equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of Adicet’s outstanding stock options and other equity securities under Adicet’s equity incentive plans. All outstanding pre-funded warrants will also be adjusted in accordance with their terms, which will result in proportionate adjustments being made to the number of shares issuable upon exercise of such warrants and to the exercise prices of such warrants, as applicable.</p>
<div class="lb-trans"><p>还将对 Adicet 的股权激励计划下授予和可发行的普通股数量进行比例调整，以及 Adicet 的未到期股票期权和其他股权证券的行使价格和可发行股份数量。所有未到期的预先融资认股权证也将根据其条款进行调整，这将导致对可通过行使这些认股权证发行的股份数量和这些认股权证的行使价格进行比例调整。</p>
</div><p>No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive fractional shares will automatically be entitled to receive cash in lieu of such fractional share.</p>
<div class="lb-trans"><p>在反向股票拆分中不会发行任何零碎股份。原本有权获得零碎股份的股东将自动有权获得现金以代替这些零碎股份。</p>
</div><p>Stockholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the consequence of the reverse stock split reflected in their accounts on or after December 30, 2025. Such beneficial holders may contact their bank, broker, or nominee for more information.</p>
<div class="lb-trans"><p>以账面形式持有股份或通过银行、经纪人或其他代理人持有股份的股东无需采取任何行动，反向股票拆分的结果将在 2025 年 12 月 30 日或之后反映在他们的账户中。这些受益持有人可以联系他们的银行、经纪人或代理人以获取更多信息。</p>
</div><p>The reverse stock split is intended to enable Adicet to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.</p>
<div class="lb-trans"><p>反向股票拆分旨在使 Adicet 重新符合纳斯达克资本市场持续上市的最低出价要求。</p>
</div><p><strong>About Adicet Bio, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Adicet Bio, Inc.</strong></p>
</div><p>Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.</p>
<div class="lb-trans"><p>Adicet Bio, Inc.是一家临床阶段的生物技术公司，专注于发现和开发用于自身免疫疾病和癌症的异体伽马δ T 细胞疗法。Adicet 正在推进一系列 “现成” 的伽马δ T 细胞，这些细胞经过嵌合抗原受体（CARs）工程改造，以促进患者的持久活性。有关更多信息，请访问我们的网站 https://www.adicetbio.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the timing and completion of the reverse stock split, the intended effects of the reverse stock split and trading of Adicet’s common stock on a split-adjusted basis, and the effect the reverse stock split will have on Adicet’s ability to regain compliance with the Nasdaq listing standards.</p>
<div class="lb-trans"><p>本新闻稿包含 Adicet 根据 1995 年《私人证券诉讼改革法》所定义的 “前瞻性声明”，涉及 Adicet 的业务和运营。词语 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将” 和类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。这些前瞻性声明包括但不限于关于反向股票拆分的时间和完成情况、反向股票拆分的预期效果以及 Adicet 普通股在拆分调整后基础上的交易情况，以及反向股票拆分对 Adicet 重新符合纳斯达克上市标准的能力的影响。</p>
</div><p>Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet’s business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; and Adicet’s ability to meet production and product release expectations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Adicet’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC), as well as discussions of potential risks, uncertainties, and other important factors in Adicet’s other filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.</p>
<div class="lb-trans"><p>本新闻稿中的任何前瞻性声明均基于管理层对未来事件的当前预期和信念，并受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些前瞻性声明中所列或暗示的结果存在重大和不利的差异，包括但不限于全球经济状况和公共卫生紧急情况对 Adicet 业务和财务结果的影响，包括对我们临床前和临床研究、业务运营、员工招聘和留任以及筹集额外资本能力的干扰；Adicet 执行其战略的能力，包括在预期时间内获得必要的监管批准（如果有的话）；临床前或临床研究的积极结果（包括中期结果）不一定能预测未来或正在进行的研究的结果；临床研究可能未能证明 Adicet 产品候选者的安全性和有效性，这将阻止、延迟或限制监管批准和商业化的范围；美国食品和药物管理局及其他外国监管机构的监管批准过程漫长、耗时且本质上不可预测；以及 Adicet 满足生产和产品发布预期的能力。有关这些及其他风险和不确定性的讨论，以及可能导致 Adicet 实际结果与前瞻性声明中所包含的结果不同的其他重要因素，请参见 Adicet 最近的 10-K 表格年度报告、10-Q 表格季度报告及其后续向美国证券交易委员会（SEC）提交的文件中标题为 “风险因素” 的部分，以及 Adicet 在 SEC 的其他文件中对潜在风险、不确定性和其他重要因素的讨论。本新闻稿中的所有信息均截至发布之日，Adicet 不承担更新该信息的义务，除非法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjY2NjE3OTNyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251226661793r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251226661793/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251226661793/en/</p>
</div><p><strong>Adicet Bio, Inc.</strong></p>
<div class="lb-trans"><p><strong>Adicet Bio, Inc.</strong></p>
</div><p><strong>Investor and Media Contacts</strong></p>
<div class="lb-trans"><p><strong>投资者和媒体联系人</strong></p>
</div><p>Anne Bowdidge</p>
<div class="lb-trans"><p>Anne Bowdidge</p>
</div><p>abowdidge@adicetbio.com</p>
<div class="lb-trans"><p>abowdidge@adicetbio.com</p>
</div><p><strong>Penelope Belnap</strong></p>
<div class="lb-trans"><p><strong>Penelope Belnap</strong></p>
</div><p><strong>Precision AQ</strong></p>
<div class="lb-trans"><p><strong>Precision AQ</strong></p>
</div><p>212-362-1200</p>
<div class="lb-trans"><p>212-362-1200</p>
</div><p>Penelope.belnap@precisionaq.com</p>
<div class="lb-trans"><p>Penelope.belnap@precisionaq.com</p>
</div><p>Source: Adicet Bio, Inc.</p>
<div class="lb-trans"><p>来源：Adicet Bio, Inc.</p>
</div>

Adicet Bio 宣布进行反向股票拆分 | ACET 股票新闻